The NM_000156.6:c.467C>A variant in GAMT is a missense variant that is predicted to cause the substitution of an alanine by an aspartic acid at amino acid position 156 (p.Ala156Asp). This variant has been detected in at least one individual with GAMT deficiency (Lei et al. Journal of Clinical Pediatrics, 2024, 42(12): 1039-1046), who was compound heterozygous for the variant and a pathogenic or likely pathogenic variant, c.194T>C (p.Leu65Pro), which was confirmed in trans by parental testing (PM3). The individual with this variant (Lei et al. Journal of Clinical Pediatrics, 2024, 42(12): 1039-1046) had elevated GAA and low or low normal creatine in urine and significantly decreased creatine peak (GAA not reported) on brain MRS (4 points; PP4_Strong). The highest population minor allele frequency in gnomAD v4.1.0. is 0.000015 (18/1180024 alleles) in the European non-Finnish population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.864 which is in the range of 0.773-0.932, evidence that correlates with impact to GAMT function at the moderate level (PP3_Moderate). Expression of the variant in HeLa cells resulted in <15% wild type GAMT activity indicating that this variant may impact protein function (PMID: 26003046); however, due to uncertainty regarding variant annotation in the publication, this was not used for PS3 evidence. There is a ClinVar entry for this variant (Variation ID: 801415). In summary, this variant meets the criteria to be classified as likely pathogenic for GAMT deficiency based on the GAMT-specific ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 2.0.0): PP4_Strong, PP3_Moderate, PM3, PM2_Supporting. (Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on December 10, 2025)